Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2009 Jun;40(6):2244-50.
doi: 10.1161/STROKEAHA.108.541128. Epub 2009 Feb 26.

Update of the stroke therapy academic industry roundtable preclinical recommendations

Marc Fisher  1 , Giora Feuerstein, David W Howells, Patricia D Hurn, Thomas A Kent, Sean I Savitz, Eng H Lo; STAIR Group
Collaborators, Affiliations
Review

Update of the stroke therapy academic industry roundtable preclinical recommendations

Marc Fisher et al. Stroke. 2009 Jun.

Abstract

The initial Stroke Therapy Academic Industry Roundtable (STAIR) recommendations published in 1999 were intended to improve the quality of preclinical studies of purported acute stroke therapies. Although recognized as reasonable, they have not been closely followed nor rigorously validated. Substantial advances have occurred regarding the appropriate quality and breadth of preclinical testing for candidate acute stroke therapies for better clinical translation. The updated STAIR preclinical recommendations reinforce the previous suggestions that reproducibly defining dose response and time windows with both histological and functional outcomes in multiple animal species with appropriate physiological monitoring is appropriate. The updated STAIR recommendations include: the fundamentals of good scientific inquiry should be followed by eliminating randomization and assessment bias, a priori defining inclusion/exclusion criteria, performing appropriate power and sample size calculations, and disclosing potential conflicts of interest. After initial evaluations in young, healthy male animals, further studies should be performed in females, aged animals, and animals with comorbid conditions such as hypertension, diabetes, and hypercholesterolemia. Another consideration is the use of clinically relevant biomarkers in animal studies. Although the recommendations cannot be validated until effective therapies based on them emerge from clinical trials, it is hoped that adherence to them might enhance the chances for success.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Stroke therapy academic industry roundtable (Fisher M, Chair) Recommendations for standards regarding preclinical neuroprotective and restorative drug development. Stroke. 1999;30:2752–2758. - PubMed
    1. O’Collins VE, Macleod MR, Donnan GA, Horky LL, van der Worp BH, Howells DW. 1,026 experimental treatments in acute stroke. Ann Neurol. 2006;59:467–477. - PubMed
    1. Savitz SI. A critical appraisal for the NXY-059 neuroprotection studies for acute stroke: A need for more rigorous testing of neuroprotective agents in animal stroke models. Exp Neurol. 2007;205:20–25. - PubMed
    1. Macleod MR, O’Collins T, Horky LL, Howells DW, Donnan GA. Systematic review and metaanalysis of the efficacy of fk506 in experimental stroke. J Cereb Blood Flow Metab. 2005;25:713–721. - PubMed
    1. Crossley NA, Sena E, Goehler J, Horn J, van der Worp B, Bath PM, Macleod M, Dirnagl U. Empirical evidence of bias in the design of experimental stroke studies: A metaepidemiologic approach. Stroke. 2008;39:929–934. - PubMed
  NODES
twitter 2